Citi lowered the firm’s price target on Lexicon (LXRX) to $1.20 from $4 and keeps a Buy rating on the shares after having updated its model for reported Q3 financial results. The firm assumes market penetration of Inpefa to be flat going forward, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon announces completion of enrollment in Phase 2B PROGRESS study
- Lexicon price target lowered to $4 from $6 at H.C. Wainwright
- Lexicon to eliminate commercial organization, focus on clinical development
- Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
- Lexicon announces data from four stories of sotagliflozin to be delivered